SNP Schneider-Neureither & Partner SE : In an accumulation phase
Entry price | Target | Stop-loss | Potential |
---|
€38 |
€32.45 |
€28.75 |
-14.61% |
---|
SNP Schneider-Neureither & Partner AG shares stand out with an interesting technical chart pattern displaying horizontal consolidation. One would assume that the current accumulation phase will cede eventually to an acceleration to the upside.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths● According to sales estimates from analysts polled by Thomson-Reuters, the company is among the best with regard to growth.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● The group usually releases upbeat results with huge surprise rates.
● Over the last twelve months, the sales forecast has been frequently revised upwards.
● The tendency within the weekly time frame is positive above the technical support level at 21.21 EUR
Weaknesses● With a 2016 P/E ratio at 25.86 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
● For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.